Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound
Links shared publicly online about this topic.
- 398total visits
Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
View full resource at news-medical.net
Tags: Hepatitis, Hepatitis B, Hepatitis B Medication, Infection, HIV Medication, Epivir, Baraclude
Most Recently Shared on April 1, 2011 at 4:59 am By:
Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound: A two-year trial... http://bit.ly/fPi8Wf
Advertisement
